Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer
Viruses · 08.04.2026 · 18 (4) · 446
DOI: 10.3390/v18040446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 08.04.2026. Verfasst von Ashwin Ganti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Fluorouracil, Cisplatin, Docetaxel. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA.
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Ashwin Ganti, Patrick W McGarrah, Harry Fuentes Bayne, Binav Baral, Daniel J Ma, Jessica M Wilson, Katharine Price
Zitieren
APA
Ganti, A., McGarrah, P. W., Fuentes Bayne, H., Fazer-Posorske, C., Baral, B., Ma, D. J., Lester, S. C., Routman, D. M., Neben-Wittich, M. A., Wilson, J. M., Price, D. L., Moore, E. J., Tasche, K. K., Van Abel, K. M., Yin, L. X., Foster, N. R., & Price, K. (2026). Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer. Viruses, 18(4), 446. https://doi.org/10.3390/v18040446
Vancouver
Ganti A, McGarrah PW, Fuentes Bayne H, Fazer-Posorske C, Baral B, Ma DJ, et al. Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer. Viruses. 2026;18(4):446. doi:10.3390/v18040446
BibTeX
@article{Ganti2026,
author = {Ganti, Ashwin and McGarrah, Patrick W and Fuentes Bayne, Harry and Fazer-Posorske, Casey and Baral, Binav and Ma, Daniel J and Lester, Scott C and Routman, David M and Neben-Wittich, Michelle A and Wilson, Jessica M and Price, Daniel L and Moore, Eric J and Tasche, Kendall K and Van Abel, Katie M and Yin, Linda X and Foster, Nathan R and Price, Katharine},
title = {Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer},
journal = {Viruses},
year = {2026},
volume = {18},
number = {4},
pages = {446},
doi = {10.3390/v18040446}
}
EUVIMED